In Re Phenylpropanolamine (PPA) Products Liability Litigation , 173 F. Supp. 2d 1377 ( 2001 )

173 F. Supp. 2d 1377 (2001)

In re PHENYLPROPANOLAMINE (PPA) PRODUCTS LIABILITY LITIGATION

No. 1407.

Judicial Panel on Multidistrict Litigation.

August 28, 2001.

Before WM. TERRELL HODGES, Chairman, JOHN F. KEENAN, MOREY L. SEAR, BRUCE M. SELYA,^[*] JULIA SMITH GIBBONS, D. LOWELL JENSEN and J. FREDERICK MOTZ,^[**] Judges of the Panel.

TRANSFER ORDER

WILLIAM TERRELL HODGES, Chairman.

Before the Panel is a motion, pursuant to 28 U.S.C. § 1407, seeking centralization at this time of the fourteen actions listed on the attached Schedule A and pending in six districts as follows: six actions in the Western District of Washington, three actions in the Eastern District of Louisiana, two actions in the District of Massachusetts, and one action each in the Western District of Louisiana, the Eastern District of Pennsylvania and the Northern District of Texas.^[1] Movants, who are plaintiffs in one of the Eastern District of Louisiana actions, seek centralization in that district. Plaintiffs in the Eastern District of Pennsylvania action support the motion. Opposed to Section 1407 transfer are all other respondents: i) plaintiffs in the six Western District of Washington actions, the two District of Massachusetts actions and a Southern District of Ohio potential tag-along action, and ii) defendants American Home Products Corp., Bayer Corp., Bristol-Myers Squibb Co., Novartis Consumer Health, Inc., Novartis Corp., Novartis Pharmaceuticals Corp., Schering-Plough Healthcare Products, Inc., and SmithKline Beecham Corp. In the event the Panel orders transfer over their objections, then various respondents offer alternative transferee districts as follows: i) plaintiffs in the Eastern District of Pennsylvania action suggest that their district would be an appropriate forum (if the Panel declines to centralize in the Eastern District of Louisiana); ii) plaintiffs in the Massachusetts actions suggest the District of Massachusetts or the Eastern District of Pennsylvania as transferee district; iii) plaintiffs in the Western District of Washington actions suggest their district; and iv) plaintiff in the Southern District of Ohio potential tag-along suggests the Central District of California.

On the basis of the papers filed and hearing session held, the Panel finds that the actions in this litigation involve common questions of fact, and that centralization under Section 1407 in the Western District of Washington will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. Notwithstanding differences among the actions in terms of named defendants, specific products involved, legal theories of recovery, status as class actions, and/or types of injury alleged, all actions remain rooted in complex core questions concerning the safety of Phenylpropanolamine (PPA) — a substance which, until it recently became the subject of a public health advisory issued by the Food and Drug Administration, was used as an ingredient in many nasal decongestants and weight control products. Centralization under Section 1407 is necessary in order to eliminate duplicative discovery, prevent inconsistent pretrial rulings (especially with respect to questions of privilege issues, confidentiality issues and class certification), and conserve the resources of the parties, their counsel and the judiciary.

Some of the opponents to transfer premise their objections, in part, on the grounds that their actions also involve unique matters not present in other actions, and that transfer would be inconvenient or economically burdensome. We note that Section 1407 does not require a complete identity or even majority of common factual and legal issues as a prerequisite to centralization. We point out that transfer under Section 1407 has the salutary effect of placing all actions in this docket before a single judge who can formulate a pretrial program that: 1) allows discovery with respect to any non-common issues to proceed concurrently with discovery on common issues, In re Joseph F. Smith Patent Litigation, 407 F. Supp. 1403, 1404 (Jud. Pan.Mult.Lit.1976); and 2) ensures that pretrial proceedings will be conducted in a manner leading to the just and expeditious resolution of all actions to the overall benefit of the parties. We observe that since Section 1407 transfer is for pretrial proceedings only, there is usually no need for the parties and witnesses to travel to the transferee district for depositions or otherwise. See, e.g., Fed.R.Civ.P. 45(c). Furthermore, the judicious use of liaison counsel, lead counsel and committees of counsel will eliminate the need for most counsel ever to travel to the transferee district. See Manual for Complex Litigation, Third, § 20.22 (1995). And it is most logical to assume that prudent counsel will combine their forces and apportion their workload in order to streamline the efforts of the parties and witnesses, their counsel and the judiciary, thereby effectuating an overall savings of cost and a minimum of inconvenience to all concerned. See In re Nissan Motor Corporation Antitrust Litigation, 385 F. Supp. 1253, 1255 (Jud.Pan. Mult.Lit.1974).

Given the range of locations of parties and witnesses in this docket, the geographic dispersal of current and anticipated constituent actions, and the wide array already of suggested transferee districts, it is clear that any one of a large number of districts would qualify as an appropriate transferee forum for this litigation nationwide in scope. In concluding that the Western District of Washington is the appropriate forum for this docket, we note that centralization in this district permits the Panel to effect the Section 1407 assignment to a major metropolitan court that i) is not currently overtaxed with other multidistrict dockets, and ii) possesses the necessary resources to be able to devote the substantial time and effort to pretrial matters that this complex docket is likely to require.

IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, the actions listed on the attached Schedule A and pending outside the Western District of Washington are transferred to the Western District of Washington and, with the consent of that court, assigned to the Honorable Barbara Jacobs Rothstein for coordinated or consolidated pretrial proceedings with the actions pending in that district and listed on Schedule A.

SCHEDULE A

MDL-14-7--In re Phenylpropanolamine (PPA) Products Liability Litigation

Eastern District of Louisiana

Aline Ricks, et al. v. American Home Products Corp., et al., C. A. No. 2:01-488 LaJeune W. Torotorich v. Bayer Corp., C.A. No. 2:01-780

Pliney Brown v. American Home Products Corp., et al., C.A. No. 2:01-781

Western District of Louisiana

Carolyn Yoakum v. Novartis Corp., et al., C.A. No. 5:01-522

District of Massachusetts

Alexander P. Ziolkowski, etc. v. Novartis Consumer Health, Inc., et al., C.A. No. 1:01-10324

Stacey Kerrigan, et al. v. Whitehall-Robins, et al., C.A. No. 1:01-10325

Eastern District of Pennsylvania

Vicki E. Hollingshead, et al. v. Bayer Corp., et al., C.A. No. 2:01-1506

Northern District of Texas

Kelley Howard v. Schering-Plough Corp., C.A. No. 1:01-47

Western District of Washington

Jane M. McCormmach, et al. v. Schering-Plough Corp., C.A. No. 2:01-303

Sandy B. Rasmussen, et al. v. Glaxosmithkline Corp., et al., C.A. No. 2:01-304

Collette Dietschi, et al. v. American Home Products Corp., C.A. No. 2:01-306

Linda Knight, et al. v. Bayer Corp., C.A. No. 2:01-307

Nancy E. French, et al. v. Bristol-Myers Squibb Co., C.A. No. 2:01-308

Linda J. Crichton, et al. v. Novartis Corp., et al., C.A. No. 2:01-309

NOTES

[*] Judges Selya and Motz took no part in the decision of this matter.

[**] Judges Selya and Motz took no part in the decision of this matter.

[1] The Panel has also been notified of additional potentially related actions now pending in the Middle, Northern and Southern Districts of Alabama, the District of Arizona, the Central District of California, the Southern District of Georgia, the Western District of Kentucky, the Middle and Western Districts of Louisiana, the Southern District of Mississippi, the District of Nebraska, the District of Nevada, the Eastern District of North Carolina, the Southern District of Ohio, the Eastern District of Pennsylvania, the District of South Carolina, the Eastern and Middle Districts of Tennessee, the Eastern, Northern and Western Districts of Texas, and the Western District of Washington. In light of the Panel's disposition of this docket, these additional actions will be treated as potential tag-along actions. See Rules 7.4 and 7.5, R.P.J.P.M.L., 199 F.R.D. 425, 435-36 (2001).